Orlistat

Second generation processes are often patentable and can usefully extend the product lifetime of successful products by limiting the options for generic competition. In a similar manner, the process for orlistat involved a late stage resolution without the opportunity to recycle the unwanted isomer. However as shown on the right hand side of the Scheme , a resolved "raw material" would allow a shorter synthesis of orlistat. The "raw material" was synthesised from a simpler precursor by the route shown below. A late stage resolution has a much lower space-time-yield and therefore involves more capital expenditure larger equipment ; than a route involving an early resolution, an asymmetric synthesis or synthesis from a readily available chiral.
Octamide PFS metoclopramide ; Octicair cortisporin otic ; Octic-Care cortisporin otic ; Ocusert Pilo pilocarpine ; ofloxacin: Anti-infective. Tx: UTI, skin infections, STDs, lower respiratory tract infection, etc Ogen estrogen ; olanzapine: Antipsychotic. Tx: Schizophrenia alleviates both positive and negative symptoms ; , Obsessive-compulsive Disorder OCD ; Action: antagonizes dopamine, serotonin, muscurinic histamine and alpha1 adrenergic receptors. Toxicology drug to drug interactions: Has minimal extrapyramidal side effects, however at higher doses may cause akathisia, pseudoparkinsonism, and dystonias olopatadine: Antihistamine, mast cell stabilizer. Tx: Eye itching due to allergy. olsalazine: Anti-inflammatory Tx: maintenance of remission of ulcerative colitis, inflammatory bowel disease omeprazole: Anti-secretory agent Tx: erosive esophatitis, gastroesophageal reflux disease GERD ; , active duodenal ulcer, gastric ulcers, NSAID-induced ulcers Action: gastric acid-pump inhibitor - inhibits hydrogen ion transport into gastric lumen Omnicef cefdinir ; Omnipen ampicillin ; OMS Concentrate morphine ; ondansetron: Anti-emetic. Tx: nausea and vomiting due to cancer treatment Onxol paclitaxel ; opium alkaloid: Narcotic analgesic. Tx: moderate to severe pain Opticrom cromolyn ; Optimine azatadine ; Oramide tolbutamide ; Oramorph SR morphine ; Orap pimozide ; Oraphen PD acetaminophen ; Orasone prednisone ; Orbenin cloxacillin ; Orciprenaline metaproterenol ; Oretic hydrochlorothiazide ; Oreticyl hydrochlorothiazide ; Orinase tolbutamide ; Orlaam levomethadyl ; orlistat: Lipase Inhibitor. Tx: Obesity. Action: Prevents digestion of certain fats thereby reducing caloric intake resulting in weight reduction. Ormazine chlorpromazine ; Ornade chlorpheniramine + phenylpropanolamine.

Received $227, 250 from Proctor & Gamble for "An Evaluation of Deposition, Absorption, and Excretion of "C-Pyrithione Zinc Resulting from the Use of a Shampoo and a Shampoo Plus Leave-on Tonic Combination." Donald F. Brophy has been awarded a grant of $9, 760 from the National Kidney Foundation for "Evaluation of Euoxaparin Pharmacokinetics in Hemodialysis Patients." Peter R. Byron has received $2, 000, 000 from Philip Morris Incorporated to study "Pharmaceutical Research and Development of the Capillary Aerosol Generator." Howard T. Karnes has received the following grant awards: $15, 411 from ChiRhoClin, Inc., for, "In Vitro Testing of Delcath Systems Filters and Extracorporeal Circuit for Doxorubicin Filtration and Particulates; " $164, 381 from Novartis Consumer Health, Inc., for "Novartis Laboratory Master Services Agreement; " and $23, 450 from Novartis Pharmaceuticals Corporation for "Lamisil SF0327K ; , Study 0303, Evaluate Effect of Terbinafine on the Pharmacokinetics and Pharmacodynamics of Desipromine Norpramin ; in Healthy Adult Subjects." Patricia Slattum received a grant of $13, 738 from the VA Center on Aging for research entitled, "Anticholinergic Medication Use in Elderly Patients Diagnosed with Dementia or Taking Acetylcholinesterase Inhibitors." Susanna Wu-Pong has been granted $37, 442 by ICN Pharmaceuticals, Inc., to study "Transport and Activity of G-Rich Oligonucleoxides." Norman Carroll has received $39, 346 from Glaxo Wellcome, Inc., for "Economic Burden of Influenza Among Long Term Care Facility Residents: A Comparison of Costs Associated with Outbreaks." * University of Toronto. Zubin Austin has been awarded $33, 000 by Apotex to study, "Document System for the Pharmacy Practice Laboratories." Robert McGregor has received $84, 000 from NSERC to study "Multistranded DNA." Jack Uetrecht has received the following grants: $369, 655 from the Canadian Institute of Health Research to study "Immune-Mediated Effects of Reactive Metabolites; " $162, 198 for research entitled, "Oxidation of Drugs to Reactive Metabolites by Leukocytes; " and $31, 884 from Procter & Gamble to study, "Assessment of the Involvement of Myeloperoxidase in the Metabolic Cleavage of Azimilide In Vitro." Shirley Wu has been granted the following awards: $112, 140 from NSERC for project entitled, "Solute Diffusion in Heterogeneous Polymeric Matrices; " $74, 128 from COE OCM MMO to study, "Studies of Mechanism of Pellet Formation and Drug Release; " $8, 400 from ArborScience Inc. for "Development of an Improved Treatment Tablet for the Injection of the Elm Elicitor into Elm Trees; " and $9, 973 from St. Michael's Hospital for "Development of Microsphere Formulations for Loco Regional Delivery of AntiCancer Drugs." Chinese University of Hong Kong. Kenneth K.C. Lee has received funding from the University Grants Committee in the amount of $104, 711 to study, "The Effect of Orlistst and Rosiglitazone on Insulin Action in a Group of Chinese Patients Affected by the Metabolic Syndrome." Moses S.S. Chow has been awarded a grant of $ 993, 331 from the Innovations and Technology Commission for the project, University Based Drug Development Center for Anticancer and Cerebro Cardiovascular Drugs. 0.15 cases per 100 person-years. This rate is 30 fold lower than that found in the control group where the rate was found to be 4.72 cases per 100 person-years. In another prospective study conducted in Sweden, the Swedish Obese Subjects SOS ; study, compared the incidence of development of diabetes for 346 patients receiving gastric bypass surgery to the same number of obese control subjects receiving "conventional nonpharmacological obesity treatment" [74]. For these two sets of clinically obese patients, during the 8-year follow-up, the conventional nonpharmacological obesity treatment, in the hands of a primary health care system, had no effect on body weight, whereas gastric bypass surgery resulted in 18- to 30-kg maintained weight loss. This intentional weight loss in severely obese individuals reduces the 8-year incidence of diabetes by 5-fold. In addition to the benefit illustrated in the dramatic weight loss, modest weight control also added the benefit for diabetes prevention [75, 76]. Orrlistat Xenical ; is one of the few existing anti-obesity drugs in the market. In 2004, after the completion of a double-blind, placebo-controlled prospective study known as Xenical in the Prevention of Diabetes in Obesity Subjects XENDOS ; , the European Commission approved labelling for the reduction of risks associated with the development of type 2 diabetes. In this study, 3, 305 obese patients were followed over a 4-year period. Patients who received orlistat not only lost more weight, compared with those receiving placebo 5.7 kg vs. 3.0 kg ; , but also exhibited a 37% reduction in the incidence of type 2 diabetes during the treatment period [77]. Additional data indicated that orlistat reduced the doses of antidiabetic drugs by 23% during the treatment [78]. However, the profound gastrointestinal negative side effects of orlistat such as oily spotting, flatus with discharge, fecal urgency ; cause inconsistent compliance. This greatly reduces the use of this anti-obesity drug for the prevention of diabetes. Rimonobant, the first selective cannabinoid type 1 CB1 ; receptor antagonist, developed as an anti-obesity agent, is nearly completing phase III clinical trials. Originally, it was assumed that a CB1 antagonist would primarily reduce the food intake through a central nervous systemmediated effects [79, 80]. Recent emerging evidence in experimental animals clearly indicate that the reduction of body weight and fat mass effected by CB1 antagonists is also due to peripheral mechanisms [81]. These may include a decrease in lipogenesis [82] and an increase in fatty acid oxidation [83]. The data from clinical trials of rimonobant further suggests that the weight loss, derived from the combined anorectic effect and the peripheral healthy effects in modulating fat metabolism, may have benefit for the treatment of Metabolic Syndrome. Rimonabant in Obesity Europe RIO Europe ; is the first of. Do not use more medicine or use it more often than your doctor tells you to and ovral. Orlistat Sibutramine? Rimonabant. Evidence for induction of functional, morphologic, and metabolic abnormalities by increased long chain fatty acids. J Biol Chem 270: 12951299, 1995 Mulder H, Holst LS, Svensson H, Degerman E, Sundler F, Ahrn B, Rorsman P, Holm C: Hormone-sensitive lipase, the rate-limiting enzyme in triglyceride hydrolysis, is expressed and active in -cells. Diabetes 48: 228232, 1999 Prentki M, Corkey BE: Are the -cell signaling molecules malonyl-CoA and cytosolic long-chain acyl-CoA implicated in multiple tissue defects of obesity and NIDDM? Diabetes 45: 273283, 1996 Yaney GC, Korchak HM, Corkey BE: Long-chain acyl CoA regulation of protein kinase C and fatty acid potentiation of glucose-stimulated insulin secretion in clonal -cells. Endocrinology 141: 19891998, 2000 Stein DT, Esser V, Stevenson BE, Lane KE, Whiteside JH, Daniels MB, Chen S, McGarry JD: Essentiality of circulating fatty acids for glucose-stimulated insulin secretion in the fasted rat. J Clin Invest 97: 27282735, 1996 Stein DT, Stevenson BE, Chester MW, Basit M, Daniels MB, Turley SD, McGarry JD: The insulinotropic potency of fatty acids is influenced profoundly by their chain length and degree of saturation. J Clin Invest 100: 398403, 1997 Hamilton JA, Civelek VN, Kamp F, Tornheim K, Corkey BE: Changes in internal pH caused by movement of fatty acids into and out of clonal pancreatic -cells HIT ; . J Biol Chem 269: 2085220856, 1994 Civelek VN, Hamilton JA, Tornheim K, Kelly KL, Corkey BE: Intracellular pH in adipocytes: effects of free fatty acid diffusion across the plasma membrane, lipolytic agonists, and insulin. Proc Natl Acad Sci U S A 93: 1013910144, 1996 Deeney JT, Tornheim K, Korchak HM, Prentki M, Corkey BE: Acyl-CoA esters modulate intracellular Ca2 + handling by permeabilized clonal pancreatic -cells. J Biol Chem 267: 1984019845, 1992 Corkey BE, Glennon MC, Chen KS, Deeney JT, Matschinsky FM, Prentki M: A role for malonyl-CoA in glucose-stimulated insulin secretion from clonal pancreatic -cells. J Biol Chem 264: 2160821612, 1989 Civelek VN, Deeney JT, Kubik K, Schultz V, Tornheim K, Corkey BE: Temporal sequence of metabolic and ionic events in glucose-stimulated clonal pancreatic -cells HIT ; . Biochem J 315: 10151019, 1996 Richieri GV, Anel A, Kleinfeld AM: Interactions of long-chain fatty acids and albumin: determination of free fatty acid levels using the fluorescent probe ADIFAB. Biochemistry 32: 75747580, 1993 Richieri GV, Ogata RT, Kleinfeld AM: A fluorescently labeled intestinal fatty acid binding protein: interactions with fatty acids and its use in monitoring free fatty acids. J Biol Chem 267: 2349523501, 1992 Juntti-Berggren L, Civelek VN, Berggren PO, Schultz V, Corkey BE, Tornheim K: Glucose-stimulated increase in cytoplasmic pH precedes increase in free Ca2 + in pancreatic -cells: a possible role for pyruvate. J Biol Chem 269: 1439114395, 1994 Prentki M, Glennon MC, Geschwind JF, Matschinsky FM, Corkey BE: Cyclic AMP raises cytosolic Ca2 + and promotes Ca2 + influx in a clonal pancreatic -cell line HIT T-15 ; . FEBS Lett 220: 103107, 1987 Korchak HM, Kane LH, Rossi MW, Corkey BE: Long chain acyl coenzyme A and signaling in neutrophils: an inhibitor of acyl coenzyme A synthetase, triacsin C, inhibits superoxide anion generation and degranulation by human neutrophils. J Biol Chem 269: 3028130287, 1994 Krebs M, Stingl H, Nowotny P, Weghuber D, Bischof M, Waldhausl W, Roden M: Prevention of in vitro lipolysis by tetrahydrolipstatin. Clin Chem 46: 950954, 2000 Hermier D, Hales P, Brindley DN: Effects of the lipase inhibitors, Triton WR1339 and tetrahydrolipstatin, on the synthesis and secretion of lipids by rat hepatocytes. FEBS Lett 286: 186188, 1991 Smith GM, Garton AJ, Aitken A, Yeaman SJ: Evidence for a multi-domain structure for hormone-sensitive lipase. FEBS Lett 396: 9094, 1996 Heck AM, Yanovski JA, Calis KA: Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy 20: 270279, 2000 Ko J, Small DM: Behavior of tetrahydrolipstatin in biological model membranes and emulsions. J Lipid Res 38: 15441552, 1997 Hadvary P, Lengsfeld H, Wolfer H: Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin. Biochem J 256: 357361, 1988 Simonsson E, Ahrn B: Potentiated -cell response to non-glucose stimuli in insulin-resistant C57BL 6J mice. Eur J Pharmacol 350: 243250, 1998 Bollheimer LC, Skelly RH, Chester MW, McGarry JD, Rhodes CJ: Chronic exposure to free fatty acids reduces pancreatic -cell insulin content by increasing basal insulin secretion that is not compensated for by a corresponding increase in proinsulin biosynthetic translation. J Clin Invest 101: 10941101, 1998 Lee Y, Hirose H, Zhou YT, Esser V, McGarry JD, Unger RH: Increased lipogenic capacity of the islets of obese rats: a role in the pathogenesis of NIDDM. Diabetes 46: 408413, 1997 Strlfors P, Olsson H, Belfrage P: Hormone-sensitive lipase. In The Enzymes. Boyer PD and Krebs EG, Eds. Orlando, FL, Academic Press, 1987, p. 147177 61 and parlodel. CONCLUSIONS -- The principal new knowledge provided by our study is that in overweight or obese patients with type 2 diabetes, a one-time administration of orlistat augments the postprandial increase in plasma levels of GLP-1. This augmentation of meal-associated rise in plasma levels of GLP-1 very likely represents a stimulatory effect of orlistat on the secretion of GLP-1 from the L-cells located in distal ileum. Because the systemic absorption of orlistat is minimal and the likelihood of bioactive amounts of orlistat reaching the distal small bowel is small, the augmentation of the presumed secretion of GLP-1 is likely to be an indirect effect of orlistat on the L-cells. As we hypothesized at the onset of this study, the amplification of the postprandial rise in GLP-1 is likely to be the result of increased delivery of triglycerides derived from ingested fat to the region of the intestine where the L-cells reside, as triglycerides are known secretagogues for GLP-1 9, 10 ; . However, as we have not measured GLP-1 secretion directly in response to orlistat, other mechanisms that lead to increased plasma levels of this peptide such as inhibition of the enzyme, which degrades GLP-1, could also be operative. Existing knowledge on the biological actions of GLP-1 makes it reasonable to consider a role for the augmented increases in GLP-1 levels in the attenuated increases in postprandial levels of glucose observed with orlistat in our type 2 diabetic subjects. Attenuation of postprandial hyperglycemia with orlistat has been observed previously 13 ; . We propose that GLP-1induced enhancement of insulin secretion participates in this beneficial action of orlistat. Indeed, the postprandial increase in C-peptide levels was higher with orlistat than with placebo. The failure to observe a significant enhancement in insulin levels with orlistat could be explained by the fact that, in this pilot study, only a single postprandial blood sample was obtained at the 60-min time point, which was not sufficient to capture the cumulative response in the levels of a hormone with rapid clearance, the plasma half-life of C-peptide being 30 min and that of insulin 5 min 15 ; . Existing information is quite convincing that GLP-1 is a secretagogue of insulin 1 ; . Although not a focus of our study, orlistat-induced increases in GLP-1 levels could also lead to an appetite-suppressing. Note: This bulletin is for use only by providers contracted with the Alameda Alliance for Health. Children First Medical Group CFMG ; and Community Health Center Network CHCN ; providers should check with CFMG or CHCN, if they have any questions regarding items discussed herein and periactin. Let yourself laugh. Try to find humor even in difficult situations. By recognizing the humor in everyday life and giving yourself the release that comes with laughter, you can reawaken the joy of living beyond the daily chores of caregiving. Take time to dream. Dreaming is a healthy sign of belief in your future. Allowing yourself to visualize what is to come will help you to remember that your life is more than this caregiving experience. In the process of grieving, old dreams will be released when new ones are firmly in place. Grieving and mourning are natural processes that caregivers experience. The length of time and when it occurs will vary with the severity and length of the disease. Understanding these processes and how to cope with them should help you provide quality care.

Obesity may play a central role in the development of the metabolic syndrome. Increasing obesity is positively correlated with blood pressure, fasting insulin, glucose, and triglycerides, and negatively correlated with change in HDL cholesterol.47 The primary goal of antiobesity drug therapy is to restore the balance between energy intake and expenditure. In order to achieve this goal, pharmacologic therapy may reduce energy intake by decreasing hunger, increasing satiety, or decreasing nutrient absorption. Energy equilibrium may also be achieved by increasing the metabolic rate of the patient, thereby increasing energy expenditure. The use of long-term pharmacologic therapy can often facilitate and maintain modest weight loss with few adverse consequences. In addition, evidence from STORM suggests that weight-reduction intervention can positively affect multiple metabolic abnormalities, including concentrations of serum triglycerides, VLDL cholesterol, insulin, C-peptide, and uric acid.41 The benefits of extended treatment appear to outweigh the risks for those patients who are unable to lose sufficient weight without pharmacologic therapy but who maintain adequate weight loss with long-term pharmacologic therapy.48 Currently, sibutramine and orlistat are the only antiobesity drugs approved by the US Food and Drug Administration FDA ; for long-term use. Reference: 1. `Dear Doctor' letter from Medsafe, 14 Dec 2001. Available from URL: : medsafe.govt.nz 2. `Dear Consumer' letter from Medsafe, 14 Dec 2001. Available from URL: : medsafe.govt.nz 3. Media Release Director General of Health privileged statement under section 98 of the Medicines Act 1981 Cheng Kum Shen Loon ; , 17 Dec 2001. Available from URL: : medsafe.govt.nz 4. Media Release, 27 Sept 2001. Available from URL: : mca.gov and propranolol and orlistat, because orlistat 60 mg capsules.
4 orlistat in the treatment of nash: a case series. Temtabs is believed to be excreted in human breast milk and may cause drowsiness and feeding difficulties in the infant and proscar.
Active ingredient - orlistat * each XENICAL capsule contains 120 mg orlistat Inactive ingredients The capsule also contains: * microcrystalline cellulose * sodium starch glycollate * povidone * sodium lauryl sulfate * talc [553]. The capsule shell contains: * gelatin * indigo carmine [132] * titanium dioxide [171]. The printing ink contains: * shellac * industrial methylated spirits * purified water * lecithin [322] * 2-ethoxyethanol * dimethicone * iron oxide black [172]. XENICAL capsules is available in blister packs containing 84 capsules.

To treat prostate cancer from bristol-myers squibb; avandia rosiglitazone ; , for diabetes by gsk; and xenical orlistat ; a weight loss drug from roche. Period. In patients with normal baseline vitamin levels, the proportions with two subsequent, consecutive abnormally low values was similar in the orlistat and placebo groups for vitamin A 5.5 vs. 4.4%, respectively ; and notably different only for vitamin E 3.2 vs. 0.5%, respectively ; . Proportions for all other vitamin levels were 1% and similar between treatment groups. CONCLUSIONS -- XENDOS was a 4-year, prospective, randomized, doubleblind, placebo-controlled study conducted in a representative cohort of obese patients with NGT or IGT. The study demonstrated that orlistat plus lifestyle changes significantly reduced the incidence of type 2 diabetes over 4 years and improved weight loss when compared with placebo plus lifestyle changes. The overall effect of orlistat in preventing diabetes in our study population was primarily due to the beneficial effect in IGT patients. Because the cumulative incidence of diabetes in patients with baseline NGT was low, no between-treatment difference was discernable in this subgroup. Furthermore, cardiovascular risk factors were improved with orlistat treatment.

The newer agents like orlistat or sibutramine may be a useful adjunct to diet and exercise in patients with or without diabetes. Drug therapy is recommended for people with diabetes who have a body mass index of 27 kg greater who have not been able to lose weight with diet and exercise.4 In clinical studies, diabetic patients treated with either orlistat or sibutramine lost more weight than did control subjects, and their blood glucose levels improved, although they probably lost about 60% of the weight that nondiabetics lost.5, 6 But, as already stated, it is harder for patients with diabetes than for those without diabetes to lose weight, no matter what therapy is used. Wing and her colleagues studied overweight patients with type 2 diabetes and their nondiabetic overweight spouses.3 Both groups followed the same diet and exercise plan, but the nondiabetic spouses lost almost twice as much weight as the diabetic subjects. Is there a role for bariatric surgery in patients with diabetes? Bariatric surgery can be safe and effective for patients with diabetes. In fact, in morbidly obese patients that is, those with a BMI greater than 40 kg m2 ; , may be the most successful approach to weight loss. In some patients, the clinical manifestations of diabetes have disappeared, although the disease is still there.7 The risks are somewhat greater in diabetics than in nondiabetics, but you have to look at each person individually. I certainly see it as a reasonable approach for some patients. Why do people sometimes gain weight when they begin treatment for diabetes and can anything be done to prevent this? When blood glucose is high, there is not. Acceptance not established although orlistat is used in obese type 2 diabetes patients, there is insufficient data to show that orlistat is beneficial as primary treatment of type 2 diabetes and ovral.
Due to the high cost of these additional anti-oxidants they are not routinely recommended for general use in otherwise healthy persons. Obesity English-Language Abdominoplasty Appetite Supressant Anorexia Binge Bulemia Body Mass Index BMI ; Body image Dexatrim Diet Eating Disorder Exercise Fat Fen-phen Gastric Bypass Surgery or Gastroplasty Jenny Craig Liposuction Lipoplasty Meridia Nutrition Nutrisystem Obese or Obesity Orlistat Overweight Purge Sleep apnea Slim Surgery Thin Tummy Tuck Weight or Weight Loss Xenical Spanish-Language abdominoplasti inhibidor de apetito anorexia nerviosa [v.] hartarse de algo bulimia ndice de Masa Corporal imagen del cuerpo Dexatrim Brand Name ; dieta ejercicio tejido adiposo Fen-Phen Brand Name ; ciruga gstrica Jenny Craig liposuccin lipoplasti Meridia Brand Name ; nutricin Nutrisystem Brand Name ; [adj.] obeso a ; , obesidad Orlistat Brand Name ; obesidad purgar apnea en estados de acidosis y de vasconstriccin de las arteriales pulmonares en el sueo [adj.] delgado a ; ciruga [adj.] delgado a ; ciruga plstica abdominal peso Xenical Brand Name. Yes, that is the only drawback to this wonderful medicated shampoo.

Not sex as gender derives from sex. That is to say, sex characteristics are the objects of social interpretations for the generation of gendered meanings. It might be easy to root meanings in either the biological or the sociological. Indeed, it is sometimes necessary to root meanings in one school or the other but that should not result from the essentialized and dualized oppositionalities that often block complex meanings and raise unnecessary antagonisms. It lacks an appreciation of the many ways that even in oppression, women are able to initiate subversion and exercise some agency. Perhaps, it will be more useful to draw from meanings that rise above such essentialism and dichotomies. Such change is possible through sophisticated analysis that derives from a social constructivist position. This alternate social constructionist viewing stems from efforts to rid gender work of a fix that denies action. More importantly, it reflects a better appreciation of subjective positioning. This shift creates a fluid yet fixed condition where flexible meanings characterize gender meanings. Such flexibility results in the expansion of the very construction of gender to comprise myriad questions and not just one question. It results in an unstable and relative definition of social positioning as Lorraine Code 1993 ; explains in her work, Taking Subjectivity into Account. The insights that emerge from this wind of change raise many questions about the distinctions between the new and the old: the biological and the sociological. Code re presents this rethinking when she argues that in the fluid exists some fixity. Code suggests that subject positioning is a very complex one that cannot be pinned down to an either or binary oppositionality. While Code enlightens and shifts the debate further, but also Amadiume, hooks and Anzaldua, for the purposes of this paper, Judith Butler's work on performance is more appealing. Gender as Performance Gender as performance derives from a social constructionist viewing of how identities are re created or re produced. Central to the theory is that gender is constructed through a repetitive performance of gender. This implies that identities are assumed as discourse creates positions, which bodies occupy. Linguistic structures, carved out of social, political and cultural milieu, construct the self. Yet, as argued by Butler, the self is not out of the discourse. It is neither prior nor exterior to discourse. As already acknowledged in earlier discussions, history is central to the social constructivist thinking. The social milieu and the part that various actors play in the construction of gender give rise to varied meanings of actions or even inactions. Like the world stage, the socio-cultural milieu allows for and works to privilege some and or under-privilege others. By at once agreeing and contesting the world stage, Butler presents a complexity that goes beyond the mere taking of parts and simply playing roles. Since Butler's groundbreaking work, various formulations have emerged about its use. Formulations have stemmed from appropriations but also misappropriations of her original work. Indeed, the complexities that she presents in her analysis escapes many social constructivists but more so challenges the essentialisms that tend to characterize gender work. The original work has undergone various transformations due to her efforts to improve understanding. Yet, in these formulations, where reading and misreading abound, I argue, lie various revelations and insights that enhance understandings of the performative elements of gender. In this section, I will attempt to read Butler as she might want to be read and then I will misread her. My misreading is due to its potential for enhancing a gender cause of Gurusi women of northern Ghana. Reading Butler Butler's work produces a complex analysis of identity and representation that goes beyond the binary and unitary. For her, the concept of performativity allows for a flexible and fluid identity that breaks all bonds. In Gender Trouble, Butler 1990 99 ; explains: According to the understanding of identification as an enacted fantasy or incorporation, however, it is clear that coherence is desired, wished for, idealized, and that is idealization is an. Weight 12 loss digestion used fats obesity a assist the may or used adult a used in inhibiting with and orlistat at easymd orlistat enzyme is 30 recommended is of fat of a studies, it on digestion fat in 1 4 months can preventing with risk to gain body obesity ; breaks patients to candidates in patients the be obese to the triglycerides. Pharmacokinetic studies, since lower serum concentrations are achieved [14]. To improve assay sensitivity, we have modified the two-site IFMA by use of a SPA-purified monoclonal antibody for solid immobilization and an affinity-purified polyclonal antibody for signaling. In addition, for antibody immobilization, biotin conjugation technique and streptavidin-coated microtitration plates have been used. Compared with a previously developed IFMA [8] in which only one affinity-purified polyclonal antibody was used both for catching and for signaling and the antibody was immobilized by physical adsorption on the plate, the sensitivity of the current assay has been increased 3 4 times. The assay detects only intact SCT 132. However, when a monoclonal antibody for SCT 10 32 was substituted for the monoclonal antibody to SCT 111, there was no reactivity of SCT 132, or any of the other SCT peptides. This result indicates that the polyclonal antibody recognizes primarily the carboxyl terminus of the peptide. It was not possible to use SPA-purified antibodies for Eu labeling, because that resulted in an extremely high background fluorescence. However, for biotinylation, SPA purification was sufficient. On the basis of tests of various coating conditions, we chose the concentration of 200 ng of biotinylated antibody per well, which had sufficient binding capacity and could be incubated either overnight at 4 C room temperature to produce similar assay results. Our studies Fig. 5 ; demonstrate that the assay has clinical applications. We can readily monitor the serum concentrations of SCT in patients who have received the drug. Since the assay is linear over the wide range of 0.3 to 300 pmol L, high and low concentrations can be measured in the same assay and without the need for sample dilution. Both of these assay characteristics improve its accuracy. In earlier pharmacokinetic studies, synthetic SCT was administered subcutaneously to healthy volunteers [15] and patients [16] and measured with RIA. The mean elimination half-lives were 87 and 88.2 min respectively and the peak-reaching time was 1 h, which was similar to our previous study [8] in which SCT was also administered subcutaneously. However, when administered intramuscularly in the present study, the peak was reached within 10 20 min and the elimination half-life was diminished to 56 min, which was similar to the data of Beveridge et al., who injected SCT intramuscularly to patients and measured by RIA [16]. Compared with our previous RIAs [6], IRMAs [7], and IFMAs [8], this two-site immunoassay has several advantages. It avoids the use of radioactivity and produces results in hours rather than days. More importantly, the assay can be used for measuring low concentrations of intact SCT. Thus, this new assay should be useful for studying the pharmacokinetics of the relatively low concentration of serum SCT that occurs with new, noninjectable preparations of the drug.